Antonella Rigo
Overview
Explore the profile of Antonella Rigo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
568
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rigo A, Vaisitti T, Laudanna C, Terrabuio E, Micillo M, Frusteri C, et al.
Cell Death Dis
. 2024 May;
15(5):323.
PMID: 38724507
Richter's syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into a high-grade B-cell malignancy. Molecular and functional studies have pointed out that CLL cells are close to the...
2.
Ferrarini I, Gandini F, Zapparoli E, Rigo A
Curr Oncol
. 2022 Apr;
29(4):2792-2797.
PMID: 35448201
Patients with chronic lymphocytic leukemia (CLL) relapsing on ibrutinib are often treated with the Bcl-2 inhibitor venetoclax. However, the transition from one agent to another poses some clinical challenges due...
3.
Ferrarini I, Rigo A, Visco C
Haematologica
. 2022 Jan;
107(4):790-802.
PMID: 35045693
Mitochondria are critical organelles in the regulation of intrinsic apoptosis. As a general feature of blood cancers, different antiapoptotic members of the BCL-2 protein family localize at the outer mitochondrial...
4.
Montresor A, Toffali L, Fumagalli L, Constantin G, Rigo A, Ferrarini I, et al.
J Immunol
. 2021 Jun;
207(2):671-684.
PMID: 34162728
The regulatory role of protein tyrosine kinases in β- and β-integrin activation and in the survival of chronic lymphocytic leukemia (CLL) cells is well established. In contrast, the involvement of...
5.
Ferrarini I, Rigo A, Visco C, Krampera M, Vinante F
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33327433
Classic Hodgkin lymphoma (cHL) is a unique lymphoid neoplasm characterized by extensive immune infiltrates surrounding rare malignant Hodgkin Reed-Sternberg (HRS) cells. Different subsets of T and NK cells have long...
6.
Rigo A, Ferrarini I, Lorenzetto E, Darra E, Liparulo I, Bergamini C, et al.
Cell Death Dis
. 2019 Nov;
10(12):889.
PMID: 31767857
α-Bisabolol (BSB) is a plant-derived sesquiterpene alcohol able to trigger regulated cell death in transformed cells, while deprived of the general toxicity in several mouse models. Here, we investigated the...
7.
Ferrarini I, Rigo A, Zamo A, Vinante F
Leuk Lymphoma
. 2019 Jul;
60(14):3395-3405.
PMID: 31304817
In classical Hodgkin lymphoma (cHL), the significance of the interplay between Hodgkin and Reed-Sternberg cells (HRS) and reactive T cells remains poorly defined. By immunohistochemistry on bioptic cHL specimens, we...
8.
Ferrarini I, Rigo A, Gandini A, Vinante F
Mediterr J Hematol Infect Dis
. 2019 Jun;
11(1):e2019033.
PMID: 31205637
West Nile virus is a zoonotic agent causing life-threatening encephalitis in a proportion of infected patients. Older age, immunosuppression, and mutations in specific host genes (e.g., CCR5 delta-32 mutation) predispose...
9.
Ferrarini I, Rigo A, Montresor A, Laudanna C, Vinante F
Oncotarget
. 2019 Apr;
10(20):1943-1956.
PMID: 30956776
Ibrutinib is increasingly adopted for treating lymphoid malignancies. While growing amounts of data pile up about Ibrutinib mechanism of action on neoplastic B cells, little is known about its impact...
10.
Montresor A, Toffali L, Rigo A, Ferrarini I, Vinante F, Laudanna C
Oncotarget
. 2018 Nov;
9(80):35123-35140.
PMID: 30416684
Bruton's tyrosine kinase (BTK) regulates the B-cell receptor (BCR) signaling pathway, which, in turn, plays a critical role in B-cell chronic lymphocytic leukemia (B-CLL) pathogenesis. The BTK-specific inhibitor Ibrutinib blocks...